Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Apogee Therapeutics, Inc. on June 9, 2026. The record date for the meeting was April 15, 2026, with 61,853,254 shares of voting common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors
- Mark C. McKenna: Elected (53,689,547 For; 1,515,704 Withheld).
- Jennifer Fox: Elected (52,895,552 For; 2,309,699 Withheld).
- William (BJ) Jones, Jr.: Elected (44,964,804 For; 10,240,447 Withheld). Note: This nominee received a significantly higher number of withheld votes compared to other candidates.
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the year ending December 31, 2026 (56,960,778 For; 1,361 Against; 38,644 Abstentions).
- Proposal 3: Advisory Vote on Executive Compensation
- Approved on a non-binding basis (54,324,725 For; 633,959 Against; 246,567 Abstentions).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the specific reasons for the elevated "Votes Withheld" (10.2 million) for director nominee William (BJ) Jones, Jr. compared to other nominees.
- Confirm the total number of broker non-votes (1,795,532) and their impact on the quorum and voting thresholds.
- Review the definitive Proxy Statement filed on April 24, 2026, for detailed biographies of the elected directors and the full compensation discussion.